Kornimate/medical-research-clean huggingface dataset:
the effect of training with custom-made biomechanical perturbation platform on kinetics, kinematics and electromyography in knee osteoarthritis patients

Conditions: Knee Osteoarthritis

Summary: the aim of this study is to evaluate the outcome of specific repetitive biomechanical perturbation training on motor patterns. the first hypothesis of this project is that footwear derived biomechanical challenges will convey active and passive matching biomechanical responses (i.e. kinetic, kinematic and electromyographic) trough out the musculoskeletal kinematic chain. the second hypothesis of the project is that repetitive exposure to in-situ (trough out the gait sickle) introduction to a biomechanical stimulus would generate a process of motor learning thus conveying plasticity of existing locomotor patterns and gait strategies.

design: prospective, case control setting: subjects will undergo a tailored training program utilizing a novel biomechanical system comprising four modular elements attached onto foot-worn platforms (apos system, apos - sports and medical technologies ltd. hertzlia, israel) which conveys perturbation throughout the gait sickle. pre and post training level walking will be examined via: (1) a three-dimensional motion analysis system and (2) ground reaction force analysis using force platforms (3) electro-myography system. each subject will be examined in 4 different settings patients will then participate in continued biomechanical perturbation training for 3-6 month and will then undergo a second gait examination ages eligible for study: 50 years - 75 years, genders eligible for study: none accepts patients suffering from medial compartment knee osteoarthritis

Eligibility criteria:
inclusion criteria: * inclusion criteria: 1. community-dwelling older adults. 2. symptomatic knee oa for at least 6 months, fulfilled american college of rheumatology clinical criteria for oa of the knee and radiographically assessed osteoarthritis of the knee graded 1-2 according to the kellgren \& lawrence scale. 3. ambulatory and active patients that can precipitate the gait analysis. 4. age 50-75. 5. no prior joint replacement in the lower extremity. exclusion criteria: * exclusion criteria: * knee pain due to pathologic conditions other than oa, such as rheumatoid arthritis and pseudogout. * knee with flexion contracture greater than 20°. * patients with hip problems, symptomatic lumbar spine disease, spinal cord. * ataxic gait related to neurologic disease. * patients with increased tendency to fall. * lack of physical or mental ability to perform or comply with the treatment procedure. * diabetes mellitus. * history of pathological osteoporotic fracture.
phase ⅲ trial of adjuvant chemotherapy in patients with n2-3 nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: to see the effect if a combination of concurrent chemoradiotherapy followed by different adjuvant chemotherapy in treating patients with n2-3 nasopharyngeal carcinoma(npc).

this phase ⅲ trial is studying how well radiation therapy and chemotherapy work in treating patients with newly diagnosed n2-3 nasopharyngeal cancer. radiation therapy uses high-energy x-rays to kill tumor cells. drugs used in chemotherapy, such as cisplatin and fluorouracil or cisplatin and gemcitabine, work in different ways (concurrent chemoradiotherapy followed by different adjuvant chemotherapy) to stop the growth of tumor cells.

Eligibility criteria:
inclusion criteria: * patients with newly histologically confirmed non-keratinizing (according to world health organization (who) histologically type). * original clinical staged as any t、n2-3m0（according to the american joint committee on cancer(ajcc) 7th edition） * no evidence of distant metastasis (m0). * age 18-65 years old. * ecog performance status less or equal to 1. * adequate marrow: leucocyte count ≥4000/μl, hemoglobin ≥90g/l and platelet count ≥100000/μl. * normal liver function test: alanine aminotransferase (alt)、aspartate aminotransferase (ast) \<1.5×upper limit of normal (uln) concomitant with alkaline phosphatase (alp) ≤2.5×uln, and bilirubin ≤uln. * adequate renal function: creatinine clearance ≥60 ml/min. * patients must be informed of the investigational nature of this study and give written informed consent. exclusion criteria: * who type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma. * age \ 65 years. * treatment with palliative intent. * prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer. * pregnancy or lactation. * history of previous radiotherapy (except for non-melanomatous skin cancers outside intended rt treatment volume). * prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes. * any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \>1.5×uln), and emotional disturbance.

Keywords: nasopharyngeal carcinoma;adjuvant chemotherapy
comparison of thyroid volumes in patients with and without endometrioma

Conditions: Endometrioma; Thyroid

Summary: the aim of our study is to evaluate whether there is a statistical difference between thyroid gland volume in patients with pathological diagnosis of endometriosis or endometrioma and in patients who underwent surgery for other gynecological reasons, and to reveal the presence of concomitant thyroid disease in these cases.

transcripts and proteins involved in thyroid metabolism are dysregulated in the eutopic and ectopic endometrium of endometriotic patients, leading to triiodothyronine (t3) action, resistance, and local thyroxine (t4) accumulation of the ectopic endometrium. thyroid stimulating hormone (tsh) acts as a proliferative and prooxidative hormone in all endometriums of endometriosis patients and controls. mouse studies have confirmed that endometriotic implants are larger when thyroid hormones are increased. since endometriosis is characterized by a chronic inflammatory process, the high prevalence of autoimmune thyroid diseases in patients with endometriosis may be the result of immune dysregulation observed in women with endometriosis (5). thyroid involvement has already been described in the physiology of the endometrium and ovary, and thyroid diseases are often associated with gynecological and obstetric disorders such as infertility, miscarriage or preterm delivery. despite all the links between thyroid diseases and endometriosis, there is no study related to thyroid volume in patients with endometriosis so far. thyroid volume was studied in patients with diabetes mellitus, pregnant women, and scleroderma. we believe that the evaluation of thyroid volume in patients with endometriosis will contribute to the investigation of the relationship between these two pathogenesis, and to the treatment and follow-up approach.

Eligibility criteria:
inclusion criteria: * prediagnosis of surgically planned endometrioma exclusion criteria: * patients with goiteri, * patients with past or present autoimmune thyroid dysfunction, * patietns on treatment with thyroid hormones or drugs containing iodine.
the early origins of cardiovascular disease

Conditions: Cardiovascular Disease

Summary: small body size at birth, slow weight gain during infancy and increase in body mass index after 2 years are independent risk factors for cardiovascular disease and the metabolic syndrome. there is a large gap in our understanding of how early growth affects the cardiovascular system. possible mechanisms include alterations in body composition, in cardiac structure, in vascular function, in renal function and epigenetic processes. the objective is to determine how size at birth and growth during infancy and childhood affect: body composition, cardiac structure and function, vascular and endothelial function, renal function, metabolic status and transcriptional and epigenetic characteristics.


Eligibility criteria:
inclusion criteria: * male and female volunteers students aged between 18-25 years old * having growth records exclusion criteria: * if young women subject without contraception,or pregnant

Keywords: the early origin of cardiovascular disease
assessment of pain in people with thalassemia

Conditions: Thalassemia

Summary: thalassemia is an inherited blood disorder that can result in mild to severe anemia. people with thalassemia often experience pain, but the exact sources and prevalence of pain remain unknown. this study will examine the prevalence and severity of pain in people with thalassemia who are treated with regular blood transfusions and people with thalassemia who are not treated with regular blood transfusions.

thalassemia is an inherited blood disorder in which the body makes an abnormal form of hemoglobin-the protein in red blood cells that carries oxygen. people with thalassemia often experience fatigue, shortness of breath, and pain. recent medical advances in treating people with thalassemia who receive regular blood transfusions-a standard procedure that refreshes the healthy red blood supply-have resulted in increased life spans for these people. however, with the extended life spans have come additional issues, including pain. there have been no previous research studies that have examined pain levels in people with thalassemia, and as a result, the sources and prevalence of pain remain unknown. the purpose of this study is to assess the prevalence and severity of pain, common pain sites, and the impact of pain on functioning and well-being in people with thalassemia who receive regular blood transfusions and people with thalassemia who do not receive regular blood transfusions. this study will enroll people with transfusion-dependant thalassemia and people with non-transfusion-dependant thalassemia. at a baseline study visit, participants will complete a demographic questionnaire and a pain assessment questionnaire. at months 3, 6, and 9, study researchers will telephone participants to go over the same pain assessment questionnaire again.

Eligibility criteria:
inclusion criteria: * thalassemia, as documented by clinical diagnosis, including the following: 1. b-thalassemia (intermedia or major) 2. hgb h disease 3. hgb h with non-deletional mutations (e.g., hgb h constant spring) 4. e-b-thalassemia 5. homozygous alpha thalassemia 6. other thalassemic conditions not explicitly excluded 7. thalassemia intermedia due to heterozygous b mutation with an alpha excess * participants can be of any race, ethnicity, and either gender. exclusion criteria: * thalassemia trait (i.e., single recessive b gene mutation, 2 gene alpha mutation) and thalassemia hgb s, c, or d compound heterozygotes * unwillingness or inability to complete the brief pain inventory (bpi) on a quarterly basis * has had a successful bone marrow transplant

Keywords: transfusion-dependent thalassemia non-transfusion-dependent thalassemia
coordinating center: natural history of barrett's esophagus using tethered capsule endomicroscopy

Conditions: Barrett Esophagus

Summary: the goal of this research is to follow barrett's esophagus patients for 3 years using the tethered capsule endomicroscopy device with distal scanning and a compact imaging system in a multi-site clinical study.

the progression of barrett's esophagus will be studied over time using tethered capsule endomicroscopy imaging and will be performed at 5 different clinical centers in the us, namely: massachusetts general hospital (mgh),(ma), mayo clinic jacksonville (fl), mayo clinic rochester (mn), columbia university medical center (ny), kansas city va medical center (mo). mgh will be the coordinating center of this multicenter study. dr g. tearney will serve as study sponsor investigator. the purpose of this study is to determine the natural history of barrett's esophagus using tce in subjects diagnosed with barrett's esophagus and undergoing surveillance endoscopy.

Eligibility criteria:
inclusion criteria: * subjects over the age of 18 * subjects who are capable of giving informed consent * subjects with a diagnosis of be without high grade dysplasia, intramucosal adenocarcinoma or esophageal adenocarcinoma, confirmed by endoscopic biopsy, * subjects who had or will have a standard of care egd within 15 months * subjects must have no solid food for at least 4 hours prior to the procedure, and only clear liquids for 2 hours prior to the procedure exclusion criteria: * subjects with prior endoscopic ablation or resection treatment of be at enrollment visit * subjects with esophageal fistula and/or esophageal strictures * subjects with the inability to swallow capsules * self reported pregnancy

Keywords: barrett's esophagus natural history capsule oct tethered capsule endomicroscopy
garlic in patients with febrile neutropenia

Conditions: Chemotherapy; Neutropenia

Summary: to determine the clinical effects of garlic in preventing and treatment of patients with chemotherapy related febrile neutropenia.these patients have a very high incidence of infections which are not routinely covered by the standard empiric therapy. adding a non- toxic and possibly effective therapy may reduce the risk for infections, synergize the empiric antibiotic treatment and may lessen the need for broader spectrum and more severe side effects.

patients eligible are randomized to receive placebo or garlic capsules after chemotherapy course and until leukocyte recovery.

Eligibility criteria:
inclusion criteria: fn patients expected to have at least 5 days or more of neutropenia will be eligible for treatment with garlic compounds ast/alt ≤ 3 times the upper limit of institutional laboratory normal. total bilirubin ≤ 2 times the upper limit of institutional laboratory normal. bun and creatinine should be ≤ 3 times the upper limit of institutional laboratory normal. newly diagnosed as well as previously treated patients will be eligible. exclusion criteria: history of clinically significant liver or kidney disease. patients on anti-coagulation therapy with coumadin will be excluded because of the potential garlic interference with metabolism. patients receiving concomitant chemotherapeutic treatment

Keywords: neutropenia fever garlic infection
a study of pegylated interferon (peg-ifn) alfa-2a (pegasys) in participants with chronic hepatitis d (chd)

Conditions: Hepatitis D, Chronic

Summary: this study evaluated the efficacy and safety of 48-week treatment with pegylated interferon (peg-ifn) alfa-2a (pegasys) monotherapy in participants with chronic hepatitis d (chd). treatment was followed by 24 weeks of treatment-free follow-up.


Eligibility criteria:
inclusion criteria: * positive hepatitis b surface antigen (hbsag) for at least 6 months prior to screening * positive anti-delta for at least 3 months prior to screening * positive hepatitis d virus (hdv) ribonucleic acid (rna) * a liver biopsy obtained within the past 18 months for non-cirrhotic patients and 30 months for cirrhotic patients demonstrating liver disease consistent with chronic hepatitis d (chd) * negative urine or serum pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of test drug exclusion criteria: * antiviral therapy for chd within the previous 6 months * positive hepatitis a, hepatitis c, or human immunodeficiency virus (hiv) * evidence of decompensated liver disease * other medical condition associated with chronic liver disease * women with ongoing pregnancy or who are breast feeding
intervention effect of canagliflozin on prediabetes in patients with hiv.

Conditions: PreDiabetes; Hiv

Summary: the high prevalence of prediabetes in hiv patients is also an outpost event for the further development of diabetes and cardiovascular events, as well as for the prolonged survival of hiv patients with metabolic problems and their complications. based on the well-established experience in the field of traditional diabetes with prediabetes, the combination of sglt2 inhibitors can target the pathophysiological mechanisms of hiv-induced metabolic disorders, and the results of a small pilot study of one of the representative drugs, cabergoline, in hiv-combined diabetic patients suggest its efficacy and safety in the treatment of hiv-combined diabetic patients. combined with the advantages of the concentrated disease resources of hiv patients in the investigator's unit, this study is intended to use a single-center randomized controlled clinical trial design, giving the experimental group drug combined with lifestyle intervention and the control group lifestyle combined with placebo intervention, to verify whether the combination of cabergoline and lifestyle intervention can safely and significantly change the clinical outcome of glucose metabolism, as well as the effect on body weight and pancreatic islet function of patients the study provides top clinical evidence for the treatment of these patients and suggests a new set of interventions for patients with hiv combined with prediabetes. no similar studies have been found to be innovative in the literature search, and the implementation of this study will be of great clinical value.


Eligibility criteria:
inclusion criteria: * patients with hiv infection combined with prediabetes who are not treated with antidiabetic drugs * fasting blood glucose of 6.1-6.9 mmol/l or 2-hour oral glucose tolerance test of 7.8-11.0 mmol/l * bmi \>24 kg/m2 and no more than 10% weight fluctuation in 3 months * hiv-infected patients must be on antiretroviral therapy, no significant symptoms, have hiv rna below the lower limit of detection for 3 consecutive months, and have cd4 cells greater than 200/ul exclusion criteria: * patients with diagnosed diabetes * those who are unwilling to participate or unable to cooperate * the patient has had an acute heart attack or cardiovascular disease in the last three months * positive pancreatic islet autoimmune antibody * history of pancreatitis or pancreatic cancer * pregnant or breastfeeding women * liver function aminotransferases greater than 2 times the upper limit of the normal range * patients with previous recurrent urinary tract infections * glomerular filtration rate \<45ml/min/1.73m2 * other serious co-morbidities
postoperative pain in adult patients.

Conditions: Pain, Postoperative; Surgical Procedures, Operative

Summary: each surgical intervention associated with even a minor tissue injury is a source of pain which needs to be effectively controlled. although the polish national guidelines for post-operative pain management have been published, many patients experience moderate and severe pain in the postoperative period. the aim of this study is (1) to assess pain severity among adult patients after different types of surgeries; (2) to identify demographic and clinical factors associated with postoperative pain.


Eligibility criteria:
inclusion criteria: * adult * elective surgery * the american society of anesthesiologists score 1-3 exclusion criteria: * diagnosed mental illness, alcohol abuse disorders, intellectual disability * traumatic events within the last 6 months (e.g. death, breakdown of a relationship, job loss) * problems with verbal communication

Keywords: postoperative pain anxiety depression adult
study to evaluate the efficacy, safety and tolerability of an oral aripiprazole/escitalopram combination therapy in participants with major depressive disorder (mdd)

Conditions: Major Depressive Disorder (MDD)

Summary: this will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral aripiprazole/escitalopram combination therapy in participants with mdd who have demonstrated an incomplete response to a prospective trial of escitalopram, and report a treatment history for the current mdd episode of an inadequate response to at least one and no more than three adequate trials of an approved antidepressant other than escitalopram. an inadequate response is defined as less than a 50% reduction in depressive symptom severity as assessed by the participant's self-report on the massachusetts general hospital antidepressant treatment response questionnaire (atrq) and evaluated by the investigator as part of the participant's medical and psychiatric history. an adequate trial is defined as an antidepressant treatment for at least 6 weeks duration (or at least 3 weeks for combination treatments) at an approved dose as specified in the atrq.

the study will be organized as follows: * screening phase * single-blind prospective treatment phase * single-blind continuation phase (responder) or double-blind randomization phase (non-responder) * 30 day post treatment follow-up assigned interventions: * escitalopram monotherapy * aripiprazole/escitalopram combination therapy * aripiprazole monotherapy

Eligibility criteria:
inclusion criteria: * participants with a current diagnosis of a major depressive episode. the current depressive episode must be ≥8 weeks in duration * participants willing to discontinue all prohibited psychotropic medication starting from the time of signing the informed consent and during the study period * participants with a hamilton depression rating scale (ham-d17) total score ≥18 at the baseline visit for the prospective treatment phase exclusion criteria: * lack of prior treatment with an antidepressant during the current depressive episode * participants who report treatment with adjunctive or monotherapy antipsychotic treatment during the current depressive episode * participants experiencing hallucinations, delusions or any psychotic symptomatology in the current depressive episode * participants with epilepsy or significant history of seizure disorders * participants with a clinically significant current diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder * participants who have received electroconvulsive therapy (ect) in the last 10 years

Keywords: major depressive disorder mdd depression
study estimating the impact of prevnar 13™ (13vpnc) on invasive pneumococcal disease

Conditions: Invasive Pneumococcal Disease

Summary: this study will estimate the incidence of invasive pneumococcal disease in members of the northern kaiser permanente healthcare system during each of the 5 following introduction of prevnar 13.

no sampling as no subjects are enrolled

Eligibility criteria:
inclusion criteria: * documented invasive pneumococcal disease (ipd), defined as recovery of an isolate of s pneumoniae from a normally sterile site in a member of the surveillance population. exclusion criteria: none

Keywords: pneumococcal conjugate vaccine
study of economic circumstances, service utilization, and service needs among older colon cancer patients

Conditions: Colon Cancer

Summary: the purpose of this study is to learn more about the social and financial impact of colon cancer for older patients. we want to know how cancer has affected the patient financially and socially, and to know if the patient has resource needs that have gone unmet. by doing this study, we hope to learn about resources that can reduce the financial burden from cancer.


Eligibility criteria:
inclusion criteria: * 65 years or older * newly diagnosed stage ii-iii colon cancer * receiving chemotherapy and at least 4-6 months into chemotherapy treatment, or have received chemotherapy and no more than 7 months post-treatment * sufficient cognitive capacity as determined by investigator or consenting professional * able to speak english or spanish * able to provide informed consent exclusion criteria: * n/a

Keywords: newly diagnosed colon stage ii stage iii